Results 51 to 60 of about 62,619,193 (270)
When IL-17 inhibitors fail : real-life evidence to switch from secukinumab to adalimumab or ustekinumab [PDF]
, 2018 Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors.
de Vita, Valerio +8 more
core +1 more source
Interleukin-12/23 Inhibitors: Ustekinumab
, 2016 Inhibitors of interleukin-12/23 (IL-12/23) are compounds which bind to both IL-12 and IL-23 and inactivate them.
Mahler, Stephen M. +7 more
core +1 more source
IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
Научно-практическая ревматология, 2019 Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing ...
E. L. Nasonov +3 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source
SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐23 inhibitor [PDF]
Journal of the European Academy of Dermatology and Venereology, 2020 Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID‐19 in this ...
Messina, F., Piaserico, S.
openaire +1 more source
Dermatology Practical & ConceptualIntroduction: The use of brodalumab in patients with psoriasis who have failed other biologic drugs is an under-explored topic; A variable percentage of patients still experience primary therapeutic failure, incomplete response, or progressive loss of ...
Diego Orsini +57 more
doaj +1 more source
Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations
Pediatric Blood &Cancer, EarlyView.ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan +18 more
wiley +1 more source
Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation study [PDF]
, 2023 Objectives: To compare the tolerability and effectiveness of two different classes of biological DMARDs [IL-17 and IL-23(p19) inhibitors, IL-17i and IL-23(p19)i] relative to TNF inhibitors (TNFi) regarding the drug survival rates and treatment outcomes ...
Dreyer, Lene +20 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT As part of the European Cooperative Study Group for Paediatric Rare Tumours initiative, we developed standard clinical practice guidelines for ovarian sex cord stromal tumors, based on comprehensive national and international cohort analyses, literature review, and a final expert consensus conference.
Dominik T. Schneider +15 more
wiley +1 more source
State-of-the-Art Review on the Treatment of Axial Spondyloarthritis
Medical SciencesThe term axial spondyloarthritis (axSpA) encompasses patients with both radiographic (r-axSpA) and non-radiographic (nr-axSpA) forms of the disease. These are two entities within the same family that share many genetic and pathogenic factors, but they ...
Evripidis Kaltsonoudis +3 more
doaj +1 more source